Chengdu Kanghong Pharmaceutical Group (SZSE:002773) Shareholders Have Endured a 61% Loss From Investing in the Stock Three Years Ago
Chengdu Kanghong Pharmaceutical Group (SZSE:002773) Shareholders Have Endured a 61% Loss From Investing in the Stock Three Years Ago
If you love investing in stocks you're bound to buy some losers. But long term Chengdu Kanghong Pharmaceutical Group Co., Ltd (SZSE:002773) shareholders have had a particularly rough ride in the last three year. So they might be feeling emotional about the 62% share price collapse, in that time. Furthermore, it's down 14% in about a quarter. That's not much fun for holders. Of course, this share price action may well have been influenced by the 6.0% decline in the broader market, throughout the period.
如果你喜歡投資股票,你一定會買一些失敗者。但從長遠來看成都康弘藥業集團有限公司(SZSE:002773)過去三年,股東的日子特別不好過。因此,他們可能會對那段時間62%的股價暴跌感到情緒激動。此外,它在大約四分之一的時間裡下跌了14%。對於持有者來說,這並不是什麼樂趣。當然,在此期間,這一股價走勢很可能受到了大盤6.0%跌幅的影響。
Now let's have a look at the company's fundamentals, and see if the long term shareholder return has matched the performance of the underlying business.
現在讓我們來看看該公司的基本面,看看長期股東回報是否與基礎業務的表現相匹配。
View our latest analysis for Chengdu Kanghong Pharmaceutical Group
查看我們對成都康弘藥業集團的最新分析
There is no denying that markets are sometimes efficient, but prices do not always reflect underlying business performance. One imperfect but simple way to consider how the market perception of a company has shifted is to compare the change in the earnings per share (EPS) with the share price movement.
不可否認,市場有時是有效的,但價格並不總是反映潛在的商業表現。一種不完美但簡單的方法來考慮市場對一家公司的看法是如何改變的,那就是將每股收益(EPS)的變化與股價走勢進行比較。
Although the share price is down over three years, Chengdu Kanghong Pharmaceutical Group actually managed to grow EPS by 5.8% per year in that time. This is quite a puzzle, and suggests there might be something temporarily buoying the share price. Alternatively, growth expectations may have been unreasonable in the past.
儘管股價在三年多的時間裡下跌,但在此期間,成都康弘藥業集團實際上實現了每股收益5.8%的增長。這是一個相當令人費解的問題,表明可能有什麼因素暫時提振了股價。或者,增長預期在過去可能是不合理的。
Since the change in EPS doesn't seem to correlate with the change in share price, it's worth taking a look at other metrics.
由於每股收益的變化似乎與股價的變化沒有相關性,因此值得看看其他指標。
The modest 0.9% dividend yield is unlikely to be guiding the market view of the stock. The company has kept revenue pretty healthy over the last three years, so we doubt that explains the falling share price. There doesn't seem to be any clear correlation between the fundamental business metrics and the share price. That could mean that the stock was previously overrated, or it could spell opportunity now.
0.9%的適度股息收益率不太可能指導市場對該股的看法。該公司在過去三年裡保持了相當健康的收入,因此我們懷疑這是否解釋了股價下跌的原因。基本面業務指標和股價之間似乎沒有任何明確的關聯。這可能意味著該股之前被高估了,也可能意味著現在有機會。
You can see below how earnings and revenue have changed over time (discover the exact values by clicking on the image).
你可以在下面看到收入和收入是如何隨著時間的推移而變化的(點擊圖片可以發現確切的價值)。
We know that Chengdu Kanghong Pharmaceutical Group has improved its bottom line lately, but what does the future have in store? This free report showing analyst forecasts should help you form a view on Chengdu Kanghong Pharmaceutical Group
我們知道成都康弘藥業集團最近提高了底線,但未來會有什麼?這免費顯示分析師預測的報告應該有助於您形成對成都康弘藥業集團的看法
A Different Perspective
不同的視角
Chengdu Kanghong Pharmaceutical Group shareholders are down 6.3% for the year (even including dividends), but the market itself is up 0.02%. Even the share prices of good stocks drop sometimes, but we want to see improvements in the fundamental metrics of a business, before getting too interested. Unfortunately, longer term shareholders are suffering worse, given the loss of 7% doled out over the last five years. We'd need to see some sustained improvements in the key metrics before we could muster much enthusiasm. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. Case in point: We've spotted 1 warning sign for Chengdu Kanghong Pharmaceutical Group you should be aware of.
成都康弘藥業集團股東全年下跌6.3%(即使包括股息),但大盤本身上漲0.02%。即使是好股票的股價有時也會下跌,但我們希望在對企業產生太大興趣之前,看到企業的基本指標有所改善。不幸的是,考慮到過去五年7%的虧損,較長期股東的損失更大。我們需要在關鍵指標上看到一些持續的改善,然後我們才能調動起太多的熱情。雖然值得考慮市場狀況對股價可能產生的不同影響,但還有其他更重要的因素。一個恰當的例子:我們發現了成都康弘藥業集團1個警示標誌你應該意識到。
For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket.
對於那些想要找到贏得投資這免費最近有內幕收購的不斷增長的公司名單可能就是合適的選擇。
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Chinese exchanges.
請注意,本文引用的市場回報反映了目前在中國交易所交易的股票的市場加權平均回報。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對這篇文章有什麼反饋嗎?擔心內容嗎? 保持聯繫直接與我們聯繫.或者,也可以給編輯組發電子郵件,地址是暗示Wallst.com。
本文由Simply Wall St.撰寫,具有概括性.我們僅使用不偏不倚的方法提供基於歷史數據和分析師預測的評論,我們的文章並不打算作為財務建議.它不構成買賣任何股票的建議,也沒有考慮你的目標或你的財務狀況.我們的目標是為您帶來由基本面數據驅動的長期重點分析.請注意,我們的分析可能不會將最新的對價格敏感的公司公告或定性材料考慮在內.Simply Wall St.對上述任何一隻股票都沒有持倉.